These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37399857)

  • 1. Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension.
    Dogra S; Shah S; Gitzel L; Pusukur B; Sood A; Vyas AV; Gupta R
    Curr Probl Cardiol; 2023 Nov; 48(11):101918. PubMed ID: 37399857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.
    Awosika A; Cho Y; Bose U; Omole AE; Adabanya U
    Expert Opin Investig Drugs; 2023; 32(11):985-995. PubMed ID: 37883217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone Synthase Inhibitors and the Treatment of Essential Hypertension.
    Gomez-Sanchez CE; Gomez-Sanchez EP
    J Clin Endocrinol Metab; 2023 Jul; 108(8):e638-e639. PubMed ID: 36740773
    [No Abstract]   [Full Text] [Related]  

  • 4. The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension.
    Forzano I; Mone P; Varzideh F; Jankauskas SS; Kansakar U; De Luca A; Santulli G
    Front Endocrinol (Lausanne); 2022; 13():1097968. PubMed ID: 36568122
    [No Abstract]   [Full Text] [Related]  

  • 5. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
    Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
    J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
    Freeman MW; Halvorsen YD; Marshall W; Pater M; Isaacsohn J; Pearce C; Murphy B; Alp N; Srivastava A; Bhatt DL; Brown MJ;
    N Engl J Med; 2023 Feb; 388(5):395-405. PubMed ID: 36342143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.
    Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
    Hypertens Res; 2023 Jan; 46(1):108-118. PubMed ID: 36266539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors?
    Ando H
    Hypertens Res; 2023 Apr; 46(4):1056-1057. PubMed ID: 36653520
    [No Abstract]   [Full Text] [Related]  

  • 9. Aldosterone and aldosterone synthase inhibitors in cardiorenal disease.
    Verma S; Pandey A; Pandey AK; Butler J; Lee JS; Teoh H; Mazer CD; Kosiborod MN; Cosentino F; Anker SD; Connelly KA; Bhatt DL
    Am J Physiol Heart Circ Physiol; 2024 Mar; 326(3):H670-H688. PubMed ID: 38133623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation.
    Azzam O; Nejad SH; Carnagarin R; Nolde JM; Galindo-Kiuchi M; Schlaich MP
    Br J Pharmacol; 2024 Feb; 181(3):319-339. PubMed ID: 37715452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A patent review of aldosterone synthase inhibitors (2014-present).
    Wu J; Ding X; Tan X
    Expert Opin Ther Pat; 2022 Jan; 32(1):13-28. PubMed ID: 34365871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone synthase inhibition in humans.
    Azizi M; Amar L; Menard J
    Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.
    Unger T; Paulis L; Sica DA
    Eur Heart J; 2011 Nov; 32(22):2739-47. PubMed ID: 21951628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New approaches in the treatment of hypertension.
    Oparil S; Schmieder RE
    Circ Res; 2015 Mar; 116(6):1074-95. PubMed ID: 25767291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
    Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
    Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
    Hameedi A; Chadow HL
    Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
    George J; Struthers AD
    Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldosterone synthase inhibition in hypertension.
    Andersen K
    Curr Hypertens Rep; 2013 Oct; 15(5):484-8. PubMed ID: 23917810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of aldosterone blockade in resistant hypertension.
    Egan BM; Li J
    Semin Nephrol; 2014 May; 34(3):273-84. PubMed ID: 25016399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy.
    Schumacher CD; Steele RE; Brunner HR
    J Hypertens; 2013 Oct; 31(10):2085-93. PubMed ID: 24107737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.